Clinical trial · Interventional
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
A Phase 1, Dose Escalation, Placebo-Controlled, Adaptive-Design Study to Evaluate the Safety and Immunogenicity of VXCO-102, a mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
NCT07557602CI-TRIAL-00109751not yet recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| EBV | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Biological | — | UNRESOLVED |
| VXCO-102 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Group 1
- description
- Dose 1 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8
- interventionNames
- Biological: VXCO-102
- type
- EXPERIMENTAL
- label
- Group 2
- description
- Dose 2 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8
- interventionNames
- Biological: VXCO-102
- type
- EXPERIMENTAL
- label
- Group 3
- description
- Dose 3 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 to 25 years, inclusive * Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment Exclusion Criteria: * Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation * Likely or confirmed myocarditis or pericarditis * Prior receipt of an investigational EBV vaccine * Prior receipt of a licensed vaccine within 56 days prior to Day 1 * Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study. * For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study Note: Other inclusion and exclusion criteria apply.
References
Publications (0)
Data not yet available
No reference posted for this study.